Class / Patent application number | Description | Number of patent applications / Date published |
424281100 | Virus (e.g., interferon-inducing virus, etc.) | 11 |
20110020406 | VIRAL INACTIVATION PROCESS - The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the effect of a viral inactivation procedure on the antigenicity of the inactivated virus. In particular for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The invention further provides methods to determine the antigenicity of an inactivated virus as well as methods to screen for anti-viral compounds using any one of the aforementioned methods Methods of using the inactivated and immunogenic virus thus obtained, in particular in the manufacture of a vaccine are also provided by the present invention. | 01-27-2011 |
20110059138 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE SYSTEM OF FELINES - Compositions and methods useful to enhance the development of the immune system of a growing animal are disclosed. | 03-10-2011 |
20110064772 | VIRAL ADJUVANTS - The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or compositions of the invention in a pharmaceutically acceptable carrier. Further provided are methods of producing an immune response against an immunogen in a subject comprising administering the immunogen and a viral adjuvant of the invention to the subject. | 03-17-2011 |
20110117137 | TAPASIN AUGMENTATION FOR ENHANCED IMMUNE RESPONSE - Tapasin (Tpn) is a member of the MHC Class I loading complex and functions to bridge the TAP peptide transporter to MHC Class I molecules. Metastatic human carcinomas express low levels of the antigen processing components (APCs) tapasin and TAP, and display few functional surface MHC Class I molecules. As a result, carcinomas are often unrecognizable by effector cytolytic T cells (CTLs). Tpn alone can enhance survival and immunity of mammals against tumors, but additionally, Tpn and TAP can be used together as components of immunotherapeutic vaccine protocols to eradicate tumors. | 05-19-2011 |
20120070464 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 03-22-2012 |
20120148627 | Compositions and Methods for Treatment of Neoplastic Disease - Herein we provide cDNA extracted from tumor cells, normal cells or treatment resistant tumor cells that have been transduced with virus capable of altering self and/or tumor associated antigens (VASTA) fused recombinantly to nucleic acids encoding wild type superantigens, superantigens, superantigen homologues and superantigen-tumor specific targeting molecules and further linked to a costimulatory molecule. The extracted cDNA is linked to a VASTA and delivered to tumor bearing hosts parenterally wherein they induce a tumoricidal response. These agents are also incorporated into a tumor tropic cell carrier for protected delivery to tumor. | 06-14-2012 |
20120301506 | Oncolytic Virus as an Inducer for Innate Antitumor Immunity - The present invention is directed to the administration of FusOn-H2, an HSV derived oncolytic virus, to treat tumor cells that are resistant to the lytic effect of the virus. Administration of FusOn-H2 induces the patient's innate immune responses to tumor cells via neutrophils, which are able to destroy tumors efficiently when they migrate to the tumor mass. With the induced innate antitumor immunity, FusOn-H2 is effective at eradicating tumors even when it is used at very low doses. | 11-29-2012 |
20120321668 | PEPTIDES DERIVED FROM HIV-1 gp41 TRANSMEMBRANE - The present invention relates to peptides, derivatives and analogs comprising an amino acid sequence derived from the transmembrane domain of HIV gp41 protein, pharmaceutical compositions comprising same, and uses thereof for therapy of inflammatory diseases and disorders, such as T-cell and/or monocyte mediated diseases. | 12-20-2012 |
20130078281 | ACTIVATORS OF INNATE IMMUNITY - The present invention includes IFNS activating agents that activate expression of IFN-β, activate NF-κB expression, activate an innate immune response, activate the expression of one or more cytokines, and/or induce the expression of interferon beta (IFN-β) through a RNase L and/or MDA5-dependent pathway. Such IFNS activating agents include single stranded RNAs that encode for conserved region II of the L protein of a negative stranded RNA virus, including, but not limited to, viruses of the family Paramyxoviridae. Also included are methods of making and using such IFNS activating agents and compositions and kits including such IFNS activating agents. | 03-28-2013 |
20140037695 | COMPOSITIONS AND METHODS FOR TARGETING OF TREATING NEOPLASMS - Methods for treating neoplasm, tumors and cancers, using one or more tumor treating drug carriers, haptens and anticancer drugs, alone or in combination with other antineoplastic agents or treatments, are provided. Also provided are compositions, and kits containing the composition for affecting the therapy. | 02-06-2014 |
20140186405 | Processes for Packaging Oligonucleotides into Virus-Like Particles of RNA Bacteriophages - The invention provides processes for the producing compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle. The invention further provides processes for producing nucleotide compositions comprising oligonucleotides suitable to be used in the processes mentioned before. The invention further provides nucleotide compositions obtainable by the processes of the invention and uses thereof. The invention further provides compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle, wherein said compositions are obtainable by the processes of the invention and wherein said compositions preferably comprises a purity of at least 98%, most preferably of at least 99%. | 07-03-2014 |